Academic Journal
Q2Rheumatology and Therapy
About Rheumatology and Therapy
Rheumatology and Therapy is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q2, with an SJR of 0.991 and H-index of 47.
Coverage: 2014-2026. Research categories: Immunology and Allergy (Q2); Rheumatology (Q2).
Verified field sources
- Journal Impact Factor: 3.1 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Editor(s): Roy Fleischmann MD (Editor-in-Chief) — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Rheumatoid Arthritis Research and Therapies; Spondyloarthritis Studies and Treatments; Psoriasis: Treatment and Pathogenesis; Autoimmune and Inflammatory Disorders Research; Systemic Lupus Erythematosus Research; Biosimilars and Bioanalytical Methods.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Sociodemographic and Clinical Determinants of Colchicine Adherence in Adults with Familial Mediterranean Fever: A Cross-Sectional Study
Ertugrul Cagri Bolek, Emre Bilgin, Riza Can Kardas, Levent Kilic et al.
2026-10 · DOI: 10.1007/s40744-026-00883-wUpdates on the Evaluation of Lupus Arthritis
Wei Tang, Alberto Nordmann-Gomes, Leila Khalili, Giovanna Rosas et al.
2026-10 · DOI: 10.1007/s40744-026-00879-6Real-World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Anisha B. Dua, Aditi Kadakia, Patrick Zueger, Simran Marwaha et al.
2026-10 · DOI: 10.1007/s40744-026-00880-zFertility and Birth Outcomes in Rheumatoid Arthritis: A Narrative Review
Noel L. Ermer, Lisa R. Sammaritano, Caroline H. Siegel
2026-10 · DOI: 10.1007/s40744-026-00877-8Correction: Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub‑analysis of the ProDERM Study
Rohit Aggarwal, Joachim Schessl, Zsuzsanna Bata-Csörgő, Mazen M. Dimachkie et al.
2026-10 · DOI: 10.1007/s40744-026-00873-ySubcutaneous Belimumab Demonstrates Consistent Steady-State Pharmacokinetics and is Well Tolerated in Paediatric Patients with SLE in China: An Open-Label Study
Caifeng Li, Junmei Zhang, Meiping Lu, Haiguo Yu et al.
2026-10 · DOI: 10.1007/s40744-026-00878-7Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies
Gerd R. Burmester, James Galloway, Karen Bevers, Jérôme Avouac et al.
2026-10 · DOI: 10.1007/s40744-026-00874-xLongitudinal Instability of Minimal Disease Activity Domains in Psoriatic Arthritis with Fluctuating Response: A Trajectory Analysis of a Real-World Cohort
Mauro Fatica, Fabio Massimo Perrotta, Noemi Italiano, Eneida Çela et al.
2026-10 · DOI: 10.1007/s40744-026-00876-9Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs
Taylor T. Schwartz, Hanke Zheng, Laetitia N’Dri, Sang Hee Park et al.
2026-10 · DOI: 10.1007/s40744-026-00861-2Long-term Comparative Adherence and Switch Rates in Patients Receiving Advanced Therapies for Rheumatoid Arthritis After Use of One TNF Inhibitor
Christina Charles-Schoeman, Kurt Oelke, Patrick M. Zueger, Yi Peng et al.
2026-10 · DOI: 10.1007/s40744-026-00872-zDuration of Belimumab Therapy and Timing of Initiation as Predictors of Clinical Outcomes in Childhood-Onset Systemic Lupus Erythematosus: A Real-World Retrospective Study
Baixu Sun, Shipeng Li, Fengqiao Gao, Shuo Liu et al.
2026-10 · DOI: 10.1007/s40744-026-00871-0Comparison of Systemic Corticosteroid Therapy Practices Between Pediatric and Adult Rheumatologists: A Multicenter Survey Study
Övgü Özenli Yağcı, Çisem Yıldız, Deniz Gezgin Yıldırım, Emre Bilgin et al.
2026-08 · DOI: 10.1007/s40744-026-00869-8Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice
Domniki M. Karagianni, Christina G. Katsiari, Konstantinos Bonotis, Lazaros I. Sakkas et al.
2026-08 · DOI: 10.1007/s40744-026-00868-9Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study)
Yoshiya Tanaka, Yuzo Kodama, Shingo Nakayamada, Atsushi Masamune et al.
2026-08 · DOI: 10.1007/s40744-026-00870-1Optical Spectral Transmission Imaging in Patients with Osteoarthritis: A Comparative Study with Joint Ultrasound and Clinical Markers
Konstantinos Triantafyllias, Stefanie Liverakos, Khalid K. Altamimi, Ann-Kathrin Druck et al.
2026-08 · DOI: 10.1007/s40744-026-00867-wClinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review
Jucier Gonçalves Júnior, Jamily Izabel Alves dos Santos, Samuel Katsuyuki Shinjo
2026-08 · DOI: 10.1007/s40744-026-00863-0Protective Effects of Apolipoprotein A and High-Density Lipoprotein Cholesterol Against Interstitial Lung Disease in Rheumatoid Arthritis: The Mediating Role of Systemic Inflammation
Lianzhi Chen, Jun Yuan, Jun Lu, Gengmin Zhou et al.
2026-08 · DOI: 10.1007/s40744-026-00866-xLongitudinal Trajectories and Predictors of Health-Related Quality of Life in Systemic Lupus Erythematosus: A 2-Year Longitudinal Cohort Study
Wan-Yun Hsu, Ching-Yi Lai, Li-Yun Tsai, I.-Chieh Chen et al.
2026-08 · DOI: 10.1007/s40744-026-00864-zFatigue in Sjögren’s Disease - Integrating Biomedical and Psychosocial Aspects: A Narrative Review
Xinyao Zhou, Jinzhou Chen, Pascal Cathebras, Martin Killian et al.
2026-08 · DOI: 10.1007/s40744-026-00865-yEfficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials
Raj Sengupta, Pedro M. Machado, Philippe Goupille, Martin Rudwaleit et al.
2026-08 · DOI: 10.1007/s40744-026-00862-1Reviews
Community Reviews
Version History
October 2, 2026 at 8:26 pm
October 2, 2026